{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-022088","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-06-30T12:30:18+00:00","discovered_at":"2026-06-30T12:35:02.322819+00:00","generated_at":"2026-06-30T12:35:16.003087+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Moleculin reports Annamycin CR rates 3x control in Phase 2/3 MIRACLE interim","bullets":["CR of 43% and 36% for Annamycin arms vs 12% control; CRc 50% and 57% vs 29% control (n=45, ITT).","iDMC unanimously recommended continuing; no statistical significance at interim per O'Brien-Fleming design.","Part A enrollment 67 of 90 (74%); trial remains powered at 80% for final analysis of ~282 subjects.","Results after single cycle; 75.6% of patients over 60, 31.1% pretreated with venetoclax."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-022088","json":"https://secwatch.observer/filing/0001437749-26-022088.json","markdown":"https://secwatch.observer/filing/0001437749-26-022088.md","text":"https://secwatch.observer/filing/0001437749-26-022088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926022088/0001437749-26-022088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926022088/mbrx20260630_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T12:35:16.003087+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}